A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and EU-Dupixent® in Healthy Adult Participants.

Phase 1 Recruiting 519 enrolled Chong Kun Dang Pharmaceutical Parexel · collab

RandomizedParallel-groupTriple-blindTreatment

Summary

This is a randomised, double-blind, three-arm, parallel group, single-dose, Phase 1 comparative study of CKD-706, US-Dupixent, and EU-Dupixent in healthy adult participants.

Timeline

Start: 2026-02-09
Primary completion: 2026-11-16
Completion: 2026-11-16

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CKD-706	Unknown	300 mg	Subcutaneous
Comparator	Dupilumab	Monoclonal antibody	300 mg	Subcutaneous

A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and EU-Dupixent® in Healthy Adult Participants.

Summary

Timeline

Drugs

Indications